AEON Biopharma Reports Fourth Quarter and Full Year 2023
– Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive...
Source: globenewswire.com
Migraine Program Next Steps News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Migraine Program Next Steps. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Migraine Program Next Steps Today - Breaking & Trending Today
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine
– Expect to announce topline data in Q3 2024 –– Company plans in Q1 2024 an end-of-phase 2 meeting with the FDA to discuss the Phase 3 program in ...
Source: businessinsider.com
AEON Biopharma Reports Third Quarter 2023 Financial Results - AEON Biopharma (AMEX:AEON)
– Announced topline results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the preventive treatment of episodic migraine that support advancing the program into a pivotal Phase 3 study – – Ongoing Phase 2
Source: benzinga.com
AEON Biopharma Reports Third Quarter 2023 Financial
– Announced topline results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the preventive treatment of episodic migraine that support advancing the...
Source: globenewswire.com